Dr. Michael A. Danso, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
5900 Lake Wright Dr
Norfolk, VA 23502
Who else practices at this address →
Norfolk city is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 878
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
VA license 0101241940
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Norfolk General Hospital Norfolk, VA
- Sentara Leigh Hospital Norfolk, VA
- Sentara Virginia Beach General Hospital Virginia Beach, VA
- Sentara Princess Anne Hospital Virginia Beach, VA
- Sentara Obici Hospital Suffolk, VA
Medical groups
- Virginia Oncology Associates (112 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 878
- Services billed
- 137,065
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 18,800 | 28 |
| Injection, aprepitant, 1 mg | 12,610 | 36 |
| Injection, paclitaxel, 1 mg | 10,422 | 19 |
| Injection, denosumab, 1 mg | 9,960 | 57 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 7,640 | 15 |
| Injection, fosaprepitant, 1 mg | 4,050 | 12 |
| Injection, docetaxel, 1 mg | 3,230 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,716 | 82 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,023 | 539 |
| Injection, palonosetron hcl, 25 mcg | 1,680 | 53 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Norfolk, VA | 348 |
| Anastrozole Other prescribers in Norfolk, VA | 123 |
| Exemestane | 87 |
| Verzenio (abemaciclib) | 78 |
| Ibrance (palbociclib) | 54 |
| Xarelto (rivaroxaban) Other prescribers in Norfolk, VA | 36 |
| Ondansetron Hcl Other prescribers in Norfolk, VA | 30 |
| Eliquis (apixaban) Other prescribers in Norfolk, VA | 28 |
| Dexamethasone Other prescribers in Norfolk, VA | 23 |
| Olanzapine Other prescribers in Norfolk, VA | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 16 payments worth $9,090 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $6,165 |
|---|---|
| AstraZeneca UK Limited | $1,110 |
| Genentech USA, Inc. | $803 |
| Merck Sharp & Dohme LLC | $451 |
| Gilead Sciences, Inc. | $232 |
| Array Biopharma Inc | $150 |
| Jazz Pharmaceuticals Inc. | $100 |
| Daiichi Sankyo Inc. | $79.03 |
| Consulting Fee | $7,943 |
|---|---|
| Food and Beverage | $696 |
| Travel and Lodging | $301 |
| Compensation for services other than consulting (speaking, faculty) | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Consulting Fee | $2,680 |
| AstraZeneca Pharmaceuticals LP Nov 18, 2025 | Consulting Fee | $2,010 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee DATROWAY · Oncology | $1,340 |
| Genentech USA, Inc. Nov 6, 2025 | Consulting Fee | $803 |
| AstraZeneca UK Limited Mar 11, 2025 | Consulting Fee | $555 |
| AstraZeneca UK Limited Jan 6, 2025 | Consulting Fee | $555 |
| Merck Sharp & Dohme LLC Jul 24, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Philadelphia, PA · in-kind | $301 |
| Array Biopharma Inc Jul 19, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA; BRAFTOVI; MEKTOVI · ONCOLOGY | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 27 industry-funded studies in 2025, from 10 companies. The companies reported $1,946,643 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca Pharmaceuticals LP - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP - A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC
Genentech, Inc. - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.